September 2017- Entera presents the "Enhanced bioavailability and reduced absorption variability of Oral PTH 1-34 in men" for its hypoparathyroidism drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Denver,Colorado. Primary hypoparathyroidism (PHP) is a hormone deficiency for which no oral replacement therapy is currently available. Oral PTH administration may allow for more flexibility in providing an adequate therapeutic dose, for achievement of normocalemia and normophosphatemia in patients with varied severity of hormone deficiency and response to therapy. Entera presented results from a clinical study focusing more on the control of the drug absorption while minimizing its variability. These results utilized the novel formulation technology in our oral PTH 1-34 tablets with decreased inter-subject variability and significantly increased bioavailability.